Overall Rank: 214
Category Rank: 63
SOPHiA GENETICS is the creator of a global data-sharing network – they work with customers from over 750 institutions in over 70 countries. Their network advances data-driven medicine to improve health outcomes and economics worldwide. A universal health data analytics platform for a decentralized approach to healthcare data pooling and knowledge sharing.
SOPHiA DDM™ for Oncology
Genomic-powered precision medicine is at the forefront of innovation in cancer research. Advancements in next-generation sequencing (NGS) technology has brought about a new era of cancer care, furthering their understanding of disease mechanisms and therapeutic targets.
The SOPHiA DDM™ Platform removes the complexity from genomic analysis. Their algorithm-enabled bundle solutions empower data-driven decisions at all stages of the cancer care journey through a combination of accurate healthcare data analysis, intuitive interpretation functionalities, and secure knowledge sharing.
SOPHiA DDM™ for Rare and Inherited Diseases
At SOPHiA GENETICS, they have the right solutions for you to confidently interpret next-generation sequencing data for variants associated with complex disease states. Utilize the power of the SOPHiA DDM Platform with a wide range of out of the box and custom NGS solutions to fit your workflows. Rare and inherited disease discovery is a journey which can require different testing strategies and we have solutions that adapt to suit your needs.
Pinpointing pathogenic mutations from large, complex datasets can be difficult, time-consuming, and sometimes overwhelming. Alamut™ Visual Plus is a comprehensive, full genome browser for efficient and user-friendly variant interpretation.
Advances in molecular and imaging techniques, combined with analytics, have resulted in an explosion of data, providing an unprecedented opportunity to identify novel, clinically relevant drug targets that can withstand rigorous validation processes. But while data-driven medicine holds great promise, it can be challenging to decipher and extract subtle biomarker signatures.
Jurgi Camblong, Founder and CEO
Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the data-driven medicine movement around the world.
He is a molecular biologist (published in Cell, Science and Nature), has a PhD in life sciences from the University of Geneva and an EMBA in management of technology from EPFL/HEC Lausanne.
In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz. He has since successfully led the development of the company, listed among the 50 Smartest Companies by the MIT Technology Review. Jurgi has been a member of the Advisory Council on Digital Transformation to the Swiss government and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.
Lara Hashimoto, SVP – Chief Business Officer
She started in the industry 20 years ago as a scientist at Roche Pharma based in Basel, Switzerland. She held several positions spanning pharma clinical drug development, business analytics and strategic marketing in the global organization as well as sales and operational marketing positions in the Canadian affiliate.
In 2009, Lara moved to Roche Molecular Diagnostics in California as the lifecycle leader responsible for the genomics and oncology IVD product portfolio and pipeline, launching several companion diagnostics globally. Lara then became the general manager of Roche Diagnostics New Zealand Ltd where she grew sales above market for 4 consecutive years.
Returning to the Bay Area, Lara then joined the newly formed Roche Sequencing Solutions team where she was the vice president responsible for non-invasive prenatal testing and the Nanopore Sequencer before being appointed chief commercial officer.
Growing up in Canada, Lara developed an early interest in understanding the role of genetics in common diseases. This took her from studying the genetics of multiple sclerosis at the University of Western Ontario to joining the Wellcome Trust Centre for Human Genetics at the University of Oxford, UK.
Philippe Menu, SVP – Chief Medical Officer
Dr. Philippe Menu, MD, PhD, MBA, brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology and business management consulting. He joined SOPHiA GENETICS in 2020 from McKinsey & Company, where he had spent the last 8 years serving dozens of clients in the BioPharma sector, advising global pharmaceutical companies, mid-size players and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases.
Philippe obtained his MD and PhD from the University of Lausanne, and his MBA in life sciences from the Open University Business School.
Ross Muken, SVP – Chief Financial Officer
Ross Muken joined SOPHiA GENETICS in February 2021. He was most recently the CFO and COO of Click Therapeutics.
Before joining Click, he was partner, senior managing director and head of the healthcare services & technology research team at Evercore ISI where he covered more than 50 companies across the healthcare technology & distribution, life science Tools & diagnostics, managed care & facilities and medical supplies & devices subsectors.
Prior to joining Evercore ISI, Ross served as a managing director at Deutsche Bank Securities and spent time in the equity research division of Thomas Weisel Partners. He began his career as an M&A investment banker at Bank of America Securities after earning his BS in business administration, magna cum laude, at Boston University.
Manuela Valente, SVP – Chief People Officer
Manuela Da Silva Valente is a seasoned human resources executive with more than 20 years’ experience working in international companies.
Manuela joined SOPHiA GENETICS in January 2019 from IQVIA (formerly Quintiles and IMS Health Inc.), a human data science company, where she held a number of senior human resources roles, including global senior human resources director.
Prior to this, she worked for several years at Outcome Sciences, where she successfully established the European operations and led the organization through an acquisition by Quintiles, a global clinical research organization.
Manuela obtained a bachelor’s degree in business administration from the Business Management School of Zurich and a management & human resources diploma from CEFCO Lausanne.
Used to work in fast-pacing companies, Manuela has extensive experience in aligning people strategies with business objectives and driving significant organizational and cultural changes by focusing on talent development and employee engagement.
Daan Van Well, SVP – Chief Legal Officer and General Counsel
Daan van Well, LL.M, MBA, has more than 20 years of experience as a lawyer in top-tier private practice, in-house and consulting roles. He has extensive experience in legal, governance and compliance matters.
Prior to joining SOPHiA GENETICS in June 2019, he was the head of legal at PwC in Geneva, Switzerland where he supported a variety of healthcare and other clients with company mergers and acquisitions, business development, governance and compliance matters.
Before that, after having held several in-house roles, Daan served as corporate secretary for international food retailer Ahold (currently Ahold-Delhaize), listed at the New York Stock Exchange and at AEX Euronext Amsterdam, where he oversaw all corporate activities, corporate finance and investor relations work.
He started his career as a lawyer at international law firm Loyens & Loeff in Rotterdam, The Netherlands. Daan holds an LL.M in Dutch civil law from Utrecht University and an executive MBA in management and corporate finance from HEC Lausanne.
In parallel to his legal career, Daan has co-founded low/no-alcohol craft beer company ABLOC. Daan is an avid cycling enthusiast and loves to go the extra mile.
Zhenyu Xu, SVP – Chief Scientific Officer
Dr. Zhenyu Xu is a genome scientist with a background in molecular and computational biology. Zhenyu is among the most experienced bioinformaticians in clinical NGS data analysis worldwide. He joined SOPHiA GENETICS in 2012 and is the leader of the technology team that developed the SOPHiA DDM™ platform — the universal technology for data-driven medicine.
Zhenyu holds a master’s degree from Cambridge University in computational biology and obtained his PhD at the European Molecular Biology Laboratory, where he focused on the transcriptome landscape of yeast. His PhD work systematically characterized the non-coding transcripts in yeast that lead to the unveiling that, in a majority of cases, transcriptions are bidirectional.
“My experience with SOPHiA GENETICS has demonstrated that the SOPHiA DDM platform accurately detects single nucleotide variants, indels, and CNVs in gene panels and exome-sized applications.” – Daniel Bellissimo PhD, Director University Pittsburgh Medical Center Clinical Genomics Laboratory
“I particularly like the visualization of GRCh37, GRCh38, or the mitochondrial genome, conveniently displaying regions close to the genes of interest and the option to see overlapping genes. Also, the option of knowing the impact of a variant on the overlapping gene, as the software enables analysis of several genes’ BAM sequences simultaneously” – Daniel Bellissimo, PhD, Director University Pittsburgh Medical Center Clinical Genomics Laboratory
“The integration of genomics-based artificial intelligence into oncology workflow solutions would be a major breakthrough for integrated cancer medicine and for future clinical research, which increasingly depend on the ability to select those patients most likely to respond to new therapies,” said Jan Makela, President & CEO, Imaging at GE Healthcare. ”This collaboration [with SOPHiA GENETICS] represents another step in GE Healthcare’s vision of making precision health — more efficient and personalized care — a reality.” – Jan Makela, President & CEO, GE Healthcare
“SOPHiA GENETICS is a leader in precision medicine,” said Keiji Kojima, Executive Vice President and Executive Officer, and General Manager of Smart Life Business Management Division of Hitachi, Ltd. “Hitachi is excited to start long term partnership with SOPHiA GENETICS to co-create innovative solutions for improving Quality of Life of patients by leveraging both companies’ data analytics and AI technologies.” – Keiji Kojima, Executive Vice President, Executive Officer, & General Manager of Smart Life Business Management Division, Hitachi
“These remarkable partners have displayed a deep commitment to building world-class solutions for customers — from cloud-to-edge — and represent some of the best and brightest our ecosystem has to offer,” said Rodney Clark, Corporate Vice President of Global Partner Solutions in Channel Sales and Channel Chief at Microsoft. – Rodney Clark, Corporate Vice President of Global Partner Solutions in Channel Sales & Channel Chief, Microsoft
“Genomics research is enabling a shift from a broad-based one-size-fits-all approach to a personalized experience. Pairing our industry-leading, rapidly customizable enrichment efficiency with SOPHiA GENETICS robust analytical platform provides customers an important solution to achieve clinically actionable data while saving on sequencing costs. We are excited to work with SOPHiA GENETICS to provide this new combined offering to clinical researchers around the world.” – Emily M. Leproust, Ph.D., CEO and Co-founder, Twist Bioscience
“My learning curve at SOPHiA GENETICS has been such a rich experience that I could not have found anywhere else. “Just” that is already amazing, but the mission of the company makes it even more fulfilling, because we all know that at the end of the day, our work, regardless of our role, is making a difference and contributes to save lives. Having the chance to be part of that makes it so meaningful to get up and go to work every day and gives me immense pride and joy.” – Christopher Aldridge, Support Specialist Leader
“I know I always want to be involved in interesting projects, and what I’m doing now while managing projects at SOPHiA GENETICS is keeping me so excited to see how medicine can evolve for the future. I feel like I’m part of moving solutions forward. The help SOPHiA GENETICS is providing to identify patients and match them with trials; I think this is creating paths to new possibilities.” – Marion Brayer, Senior Director Clinical Operations
“I think what we’re building will benefit my children and the generations to come. We’re creating a community that is already connecting research efforts around the world. SOPHiA GENETICS is a catalyst for solutions.” – Alexander Kurze, Director, Commercial Application Product Management